Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Posts filed under: Personalized medicine

Strimvelis (GSK2696273), a gene therapy for a deadly immunodeficiency in children, expected to reach the European market in mid-2016

TweetOur recent book-length report, Gene Therapy: Moving Toward Commercialization was published by Cambridge Healthtech Institute in November 2015. As indicated by its title, the report focuses on clinical-stage gene therapy programs that are aimed at commercialization, and the companies that are carrying out these programs. Until recently, gene therapy was thought of as a scientifically-premature…

Can adoptive cellular immunotherapy successfully treat metastatic gastrointestinal cancers?

Tweet  On September 6, 2014, we published an article on this blog announcing the publication of our book-length report, Cancer Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies, by Cambridge Healthtech Institute (CHI). In that article, we cited the example of the case of a woman with metastatic cholangiocarcinoma (bile-duct cancer), which typically…

Gene editing technology used to treat infant with leukemia

Tweet  In November 2015, the use of gene editing technology to treat an 11-month-old child with leukemia was reported in news articles in Nature and in Science. Because of the human-interest value of this story, it was also reported in Time magazine and in the New York Times. Data from this first-in-humans clinical use of…

Gene Therapy Report Published By CHI Insight Pharma Reports

Tweet  On November 6, 2015, Cambridge Healthtech Institute (CHI) announced the publication of a new book-length report, Gene Therapy: Moving Toward Commercialization, by Allan B. Haberman, Ph.D. As demonstrated by several late-breaking news items that appeared as our report was in the process of publication, gene therapy is a “hot”, fast-moving field. For example: On…

Our New Year’s 2015 article: Notable researchers and breakthrough research of 2014

Tweet  As is their customary practice, both Nature and Science ran end-of-year specials. The Nature special (in their 18 December issue) is entitled “365 days: Nature’s 10. Ten people who mattered this year.” The Science special (in their 19 December issue) is entitled, as usual “2014 Breakthrough of the Year.” As is also usual, there…

Immune checkpoint inhibitors work by reactivating tumor-infiltrating T cells (TILs)

TweetThe 27 November issue of Nature contains a wealth of new studies on how immune checkpoint inhibitors target various types of cancer, and how researchers and physicians might be able to identify the patients who are most likely to benefit from treatment with these agents. These studies are described in five papers published in that…

Vertex cystic fibrosis therapeutics update

Tweet As we said in our September 10, 2014 article, we intended to post updates on companies that we had been following on our blog, and that have achieved significant progress in recent months. So far, we have covered Agios and Zafgen. Both of these companies were featured in Boston-area meetings in October—Zafgen in Xconomy…

Cancer Immunotherapy Report Published By CHI Insight Pharma Reports

Tweet  On September 9, 2014, Cambridge Healthtech Institute’s (CHI’s) Insight Pharma Reports announced the publication of a new book-length report, Cancer Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies, by Allan B. Haberman, Ph.D. As attested by the torrent of recent news, cancer immunotherapy is a “hot”, fast-moving field. For example: On September…

Agios Pharmaceuticals continues to progress

TweetBecause of being very busy with other projects, we have not posted an article on this blog since April 10, 2014. However, the Biopharmconsortium Blog is still here. More importantly, Haberman Associates biotech/pharma consulting is still here, and we’re still accepting new clients. Thanks to the many readers who have continued to follow our website…

Breakthrough of the year 2013–Cancer Immunotherapy

TweetAs it does every year, Science published its “Breakthrough of the Year” for 2013 in the 20 December 2013 issue of the journal. Science chose cancer immunotherapy as its Breakthrough of the Year 2013. In its 20 December 2013 issue, Science published an editorial by its Editor-in-Chief, Marcia McNutt, Ph.D., entitled “Cancer Immunotherapy”. The same…